{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:17:09Z","timestamp":1783426629015,"version":"3.54.6"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.msard.2026.107292","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:50:13Z","timestamp":1780293013000},"page":"107292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antinuclear antibodies, apoptotic factors sFas and sFasL, and chemokines CXCL8, CXCL10, and CCL20 as prognostic biomarkers in multiple sclerosis"],"prefix":"10.1016","volume":"112","author":[{"given":"Josip","family":"Sremec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Ko\u0161\u0107ak Luka\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurap","family":"Raifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koraljka","family":"Ba\u010di\u0107 Baronica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Tomi\u0107 Sremec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1104-7571","authenticated-orcid":false,"given":"Berislav","family":"Ru\u0161ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Tomasovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2026.107292_bib0010","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","article-title":"Neurofilament light chain elevation and disability progression in multiple sclerosis","volume":"80","author":"Abdelhak","year":"2023","journal-title":"JAMa Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107292_bib0022","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2011.11.023","article-title":"Do we need broad immunological work-up in all patients with CIS?","volume":"315","author":"Adamec","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107292_bib0033","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2026.107292_bib0018","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood-2004-06-2364","article-title":"Induction of tolerance using Fas ligand: a double-edged immunomodulator","volume":"105","author":"Askenasy","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.msard.2026.107292_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.msard.2026.107292_bib0013","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107292_bib0021","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1212\/WNL.45.2.384","article-title":"Frequency of anti-nuclear antibodies in multiple sclerosis","volume":"45","author":"Barned","year":"1995","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2026.107292_bib0009","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107292_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.26913","article-title":"Determinants and biomarkers of progression independent of relapses in multiple sclerosis","volume":"96","author":"Calabrese","year":"2024","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107292_bib0027","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.msard.2026.107292_bib0005","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fimmu.2019.00726","article-title":"Zettl UK. The cerebrospinal fluid in multiple sclerosis","volume":"10","author":"Deisenhammer","year":"2019","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.msard.2026.107292_bib0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archneur.1982.00510200046008","article-title":"Antinuclear antibodies in multiple sclerosis","volume":"39","author":"Dore-Duffy","year":"1982","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2026.107292_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.msard.2026.107292_bib0026","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11011-020-00648-6","article-title":"A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis","volume":"36","author":"Ghafouri-Fard","year":"2021","journal-title":"Metab. Brain Dis."},{"issue":"6","key":"10.1016\/j.msard.2026.107292_bib0006","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1055\/s-0039-1700528","article-title":"Optical coherence tomography in multiple sclerosis","volume":"39","author":"Graves","year":"2019","journal-title":"Semin. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107292_bib0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/WNP.0000000000000723","article-title":"Multimodal evoked potentials as candidate prognostic and response biomarkers in clinical trials of Multiple sclerosis","volume":"38","author":"Hardmeier","year":"2021","journal-title":"J. Clin. Neurophysiol."},{"issue":"15","key":"10.1016\/j.msard.2026.107292_bib0025","doi-asserted-by":"crossref","first-page":"8064","DOI":"10.3390\/ijms25158064","article-title":"Serum concentrations of chemokines CCL20, CXCL8 and CXCL10 in relapsing-remitting multiple sclerosis and their association with presence of antibodies against Epstein-Barr Virus","volume":"25","author":"Ko\u0161\u0107ak Luka\u010d","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2026.107292_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2015.08.016","article-title":"Role of inflammation and apoptosis in multiple sclerosis: comparative analysis between the periphery and the central nervous system","volume":"287","author":"Macchi","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107292_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117471","article-title":"Biochemical biomarkers for multiple sclerosis","volume":"548","author":"Maroto-Garc\u00eda","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.msard.2026.107292_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120847","article-title":"Optical coherence tomography (OCT) measurements and disability in multiple sclerosis (MS): a systematic review and meta-analysis","volume":"454","author":"Mirmosayyeb","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107292_bib0029","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0165-5728(02)00097-8","article-title":"Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system","volume":"127","author":"S\u00f8rensen","year":"2002","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107292_bib0002","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jamaneurol.2013.599","article-title":"Early relapses, onset of progression, and late outcome in multiple sclerosis","volume":"70","author":"Scalfari","year":"2013","journal-title":"JAMa Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107292_bib0028","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1359-6101(03)00049-2","article-title":"The CC chemokine CCL20 and its receptor CCR6","volume":"14","author":"Schutyser","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.msard.2026.107292_bib0023","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/rheumatology\/39.6.581","article-title":"Antinuclear antibodies: cause of disease or caused by disease?","volume":"39","author":"Smeenk","year":"2000","journal-title":"Rheumatology. (Oxford)"},{"issue":"1","key":"10.1016\/j.msard.2026.107292_bib0031","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"12","key":"10.1016\/j.msard.2026.107292_bib0017","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.3390\/jcm9123845","article-title":"Elevated concentrations of soluble Fas and FasL in multiple sclerosis patients with antinuclear antibodies","volume":"9","author":"Sremec","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2026.107292_bib0032","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"24","key":"10.1016\/j.msard.2026.107292_bib0001","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1212\/WNL.0b013e3181e3973f","article-title":"New perspectives in the natural history of multiple sclerosis","volume":"74","author":"Tremlett","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.107292_bib0015","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190460","article-title":"Pathogenic T cell cytokines in multiple sclerosis","volume":"217","author":"Wagner","year":"2020","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.msard.2026.107292_bib0014","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.amjms.2018.08.018","article-title":"The properties of cytokines in multiple sclerosis: pros and cons","volume":"356","author":"Wang","year":"2018","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.msard.2026.107292_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101416","article-title":"Role of B cells and antibodies in multiple sclerosis","volume":"36","author":"Wanleenuwat","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107292_bib0030","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/CON.0000000000001136","article-title":"Epidemiology and pathophysiology of Multiple sclerosis","volume":"28","author":"Ward","year":"2022","journal-title":"Continuum (Minneap. Minn)"},{"issue":"11","key":"10.1016\/j.msard.2026.107292_bib0003","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.3390\/ijms23115877","article-title":"Current and future biomarkers in multiple sclerosis","volume":"23","author":"Yang","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:36:24Z","timestamp":1783424184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S2211034826003287"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107292","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antinuclear antibodies, apoptotic factors sFas and sFasL, and chemokines CXCL8, CXCL10, and CCL20 as prognostic biomarkers in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107292"}}